Page 6 - Ericm Dube News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) – Investment analysts at Jefferies Financial Group issued their Q1 2022 earnings estimates for shares of Travere Therapeutics in a research note issued to investors on Monday, April 25th. Jefferies Financial Group analyst M. Raycroft anticipates that the company will earn ($0.63) per share for the quarter. Jefferies […]

Equities research analysts forecast that Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) will post sales of $53.17 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Travere Therapeutics’ earnings. The highest sales estimate is $55.13 million and the lowest is $49.30 million. Travere Therapeutics reported sales of $47.41 million […]

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) have been given an average recommendation of “Buy” by the nine brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the […]

Travere Therapeutics (NASDAQ:TVTX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known […]

Zacks Investment Research upgraded shares of Travere Therapeutics (NASDAQ:TVTX – Get Rating) from a sell rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known […]